Dr. Alberto Lleó is the director of the Neurology Department at Hospital de la Santa Creu i Sant Pau.
After obtaining his Medical degree from the University of Barcelona, he completed his specialization in Neurology at Hospital de la Santa Creu i Sant Pau in 2000. Two years later, he obtained his PhD in Medicine at the University of Barcelona. After that, he continued his education with a clinical and basic research fellowship on memory and movement disorders at the Massachusetts General Hospital, Boston (2002-2004) where he combined clinical and research tasks.
In his professional career, Dr. Alberto Lleó has combined his clinical activity with translational research projects in the field of dementias, with a specific focus on the molecular bases of the disease and biomarker development. Some of his main contributions are the discovery of new genetic alterations in Alzheimer’s disease, the study of the gamma-secretase complex, and the assessment of new chemical biomarkers for Alzheimer’s disease and frontotemporal dementia.
Today, Dr. Alberto Lleó runs a translational group, leads many projects funded by public and private agencies, and collaborates regularly with numerous national and international research groups. He also coordinates the Alzheimer program of CIBERNED (Center for Networked Biomedical Research in Neurodegenerative Diseases). To date, he has authored more than 20 book chapters and over 150 publications in international journals, and his contributions have been awarded by the Spanish Society of Neurology.
Recent Publications
- Neurofilament Light Chain and Mutant Huntingtin Across Huntington's Disease Integrated Staging System Stages in Huntington Disease: A Cross-Sectional Multimodal Analysis. Pérez-Pérez, J, Olmedo-Saura, G, Puig Davi, A et al. Mov Disord 2026PMID:42876089
- Differentiating nonfluent/agrammatic and logopenic primary progressive aphasia in Catalan-Spanish bilinguals by applying multilingual multimodal machine learning to connected speech. Pugalenthi, LS, Collins, AP, Colomer, NM et al. medRxiv 2026PMID:42818139
- Changes in serum β-synuclein precede blood biomarkers of Alzheimer pathology in Down syndrome. Cervantes González, A, Morcillo-Nieto, AO, Serrano, S et al. Alzheimers Dement 2026PMID:42768868
- Non-motor symptoms questionnaire-based profiles in early-stage dementias: A prospective cohort study. Kinnunen, M, Vitikka, E, Krüger, J et al. J Alzheimers Dis 2026PMID:42768715
- Natural history and clinical impact of epilepsy in adults with Down syndrome: a multicentre clinical study. Maure-Blesa, L, Carmona-Iragui, M, Barroeta, I et al. Lancet 2026PMID:42692040
- Pre-dementia clinical trajectories associated with neuronal α-synuclein neuropathologic change: a retrospective cohort study. Vera-Campuzano, E, Selma-González, J, Rodríguez-Baz, Í et al. Res Sq 2026PMID:42687952
- Methodological insights and clinical outcomes in ALS and FTLD: lessons from the SPIN cohort. Carbayo, Á, Turon-Sans, J, Alcolea, D et al. Alzheimers Dement 2026PMID:42658841
- Semantic control across Alzheimer's disease phenotypes: cognitive mechanisms and neural correlates. Armas, P, Morcillo-Nieto, AO, Zsadanyi, SE et al. Front Aging Neurosci 2026PMID:42656695
- Exome analysis of 22,319 individuals links extremely rare copy-number variants and 22q11.21 dosage to Alzheimer risk. Quenez, O, Schramm, C, Cassinari, K et al. Am J Hum Genet 2026PMID:42648288
- APOEε4 attenuates early TREM2-mediated microglial responses and influences disease trajectories in dementia with Lewy bodies. Rodríguez, EM, Zaragoza-Ballester, P, Alcolea, D et al. Res Sq 2026PMID:42620051
- Plasma proteome profiling identified biomarkers for the differential diagnosis and molecular staging of neurodegenerative dementias. Bellomo, G, Vermunt, L, In 't Veld, S et al. Nat Aging 2026PMID:42477094
- Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis. Blazhenets, G, Soleimani-Meigooni, DN, Chiotis, K et al. JAMA 2026PMID:42441390
- CSF and plasma tau biomarkers in the Down syndrome-Alzheimer's disease continuum. Arranz, J, Lantero-Rodríguez, J, Braun-Wohlfahrt, LS et al. EBioMedicine 2026PMID:42435584
- The predictive power of neuropsychological measures in MCI: early detection of dementia conversion. Padilla, C, Zsadanyi, SE, Aragón, I et al. Front Aging Neurosci 2026PMID:42404240
- Cerebrospinal fluid NPTX2/p-tau ratio as a biomarker for cognitive decline in neurodegenerative diseases. Gomes, BF, Sauer, M, Montoliu-Gaya, L et al. Alzheimers Dement (Amst) 2026PMID:42326467